According to the acquisition, Catalent will receive a $16.5B all-cash payment for $63.50 per share, with a 16.5% premium to the previous closing price and a 47.5% premium to the 60-days average on Feb 2, 2024; which Reflects a strategy of investing in Life Sciences ventures
Novo Holdings plans to sell Catalent’s 3 fill-finish sites (located in Anagni, Italy; Bloomington, Indiana, US; and Brussels, Belgium) and other related assets
On May 6, 2024, the company announced a 30-day delay in the acquisition. The delay is attributed to FTC’s antitrust scrutiny on the buyout; Acquisition completion is expected by the end of 2024
Ref: Catalent | Image: Catalent
Related News:- Novo Nordisk Reports the Acquisition of Cardior Pharmaceuticals for ~$1.11B
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
